Last-Resort cancer drug made available for patients with specific gene mutations

NCT ID NCT04566393

AVAILABLE Disease control Sponsor: xCures Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly shrink tumors, but it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma colorectal cancer colorectal neoplasm esophageal cancer Esophageal Neoplasms gastric cancer gastric neoplasm glioblastoma head and neck cancer Head and Neck Neoplasms hepatocellular carcinoma malignant pancreatic neoplasm melanoma non-small cell lung carcinoma ovarian cancer pancreatic neoplasm small intestine carcinoma thyroid cancer Thyroid Neoplasms urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER BRAF GENE MUTATION CHOLANGIOCARCINOMA COLORECTAL CANCER ERK MUTATION ESOPHAGEAL CANCER GASTRIC CANCER GLIOBLASTOMA HEAD AND NECK CANCER HEPATOCELLULAR CARCINOMA HRAS GENE MUTATION KRAS ACTIVATING MUTATION MAPK GENE MUTATION MEK MUTATION MELANOMA NON-SMALL CELL LUNG CANCER NRAS GENE MUTATION OVARIAN CANCER PANCREATIC CANCER SMALL BOWEL CANCER THYROID CANCER

Contacts and locations

Locations

Atlantic Health System/Overlook Medical Center
AVAILABLE

Summit, New Jersey, 07901, United States
Cancer Partners of Nebraska
AVAILABLE

Lincoln, Nebraska, 68510, United States
Hirschfeld Oncology
AVAILABLE

Brooklyn, New York, 11206, United States
Hoag Memorial Hospital Presbyterian
AVAILABLE

Newport Beach, California, 92663, United States
Hunterdon Hematology Oncology
AVAILABLE

Flemington, New Jersey, 08822, United States
Infirmary Cancer Care
AVAILABLE

Mobile, Alabama, 36604, United States
Lake Region Healthcare
AVAILABLE

Fergus Falls, Minnesota, 56537, United States
Lehigh Valley Health Network
AVAILABLE

Allentown, Pennsylvania, 18103, United States
MD Anderson
AVAILABLE

Houston, Texas, 77030, United States
Mary Bird Perkins Cancer Center
AVAILABLE

Baton Rouge, Louisiana, 70809, United States
MedStar Georgetown University Hospital
AVAILABLE

Washington D.C., District of Columbia, 20007, United States
Mercy Medical Center
AVAILABLE

Cedar Rapids, Iowa, 52403, United States
Monmouth Medical Center
AVAILABLE

Long Branch, New Jersey, 07740, United States
Nebraska Hematology Oncology
AVAILABLE

Lincoln, Nebraska, 68506, United States
Oakland Macomb Cancer Specialists
AVAILABLE

Sterling Heights, Michigan, 48314, United States
Orlando Health
AVAILABLE

Orlando, Florida, 32806, United States
Our Lady of the Lake Hospital
AVAILABLE

Baton Rouge, Louisiana, 70808, United States
PCR Oncology
AVAILABLE

Arroyo Grande, California, 93420, United States
Providence Saint John's Health Center
AVAILABLE

Santa Monica, California, 90404, United States
Stony Brook Cancer Center
AVAILABLE

Stony Brook, New York, 11794, United States
The Christ Hospital
AVAILABLE

Cincinnati, Ohio, 45219, United States
The Minniti Center for Medical Oncology and Hematology
AVAILABLE

Mickleton, New Jersey, 08056, United States
UTHealth - Tyler
AVAILABLE

Tyler, Texas, 75701, United States
UTHealth Houston
AVAILABLE

Houston, Texas, 77030, United States
Unity Point Health - St. Lukes Hospital
AVAILABLE

Cedar Rapids, Iowa, 52403, United States
xCures Inc.
AVAILABLE

San Francisco, California, 94105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.